XORTX Therapeutics Inc. (XRTX.V)
CAD 1.62
(-7.43%)
CAD 1.62
(-7.43%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.08 Million CAD | -79.71% |
| 2022 | 5.36 Million CAD | 29.2% |
| 2021 | 4.15 Million CAD | 301.8% |
| 2020 | 1.03 Million CAD | -20.43% |
| 2019 | 1.29 Million CAD | 37.72% |
| 2018 | 943.7 Thousand CAD | -17.6% |
| 2017 | 1.14 Million CAD | 91.02% |
| 2016 | 599.52 Thousand CAD | 0.0% |
| 2014 | 60.16 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.55 Million USD | 330.96% |
| 2024 Q2 | 2.09 Million USD | -41.15% |
| 2023 Q4 | 825.93 Thousand USD | 49.15% |
| 2023 FY | 1.08 Million CAD | -79.71% |
| 2023 Q1 | 599.78 Thousand USD | -91.77% |
| 2023 Q2 | 403.26 Thousand USD | -32.77% |
| 2023 Q3 | 553.75 Thousand USD | 37.32% |
| 2022 Q1 | 5.04 Million CAD | -4.86% |
| 2022 Q4 | 7.28 Million CAD | 71.29% |
| 2022 FY | 5.36 Million CAD | 29.2% |
| 2022 Q3 | 4.25 Million CAD | 11.91% |
| 2022 Q2 | 3.8 Million CAD | -24.59% |
| 2021 Q4 | 5.29 Million CAD | -56.11% |
| 2021 Q3 | 12.07 Million CAD | 200.8% |
| 2021 Q2 | 4.01 Million CAD | -15.98% |
| 2021 FY | 4.15 Million CAD | 301.8% |
| 2021 Q1 | 4.77 Million CAD | 361.87% |
| 2020 FY | 1.03 Million CAD | -20.43% |
| 2020 Q2 | 870.86 Thousand CAD | -25.57% |
| 2020 Q1 | 1.17 Million CAD | -9.98% |
| 2020 Q4 | 1.03 Million CAD | 3.99% |
| 2020 Q3 | 994.5 Thousand CAD | 14.2% |
| 2019 Q2 | 1.06 Million CAD | 10.4% |
| 2019 FY | 1.29 Million CAD | 37.72% |
| 2019 Q1 | 965.86 Thousand CAD | 2.35% |
| 2019 Q4 | 1.29 Million CAD | 10.43% |
| 2019 Q3 | 1.17 Million CAD | 10.37% |
| 2018 Q4 | 943.7 Thousand CAD | 5.24% |
| 2018 Q2 | 828.74 Thousand CAD | 0.83% |
| 2018 Q3 | 896.67 Thousand CAD | 8.2% |
| 2018 Q1 | 821.89 Thousand CAD | -28.23% |
| 2018 FY | 943.7 Thousand CAD | -17.6% |
| 2017 Q2 | 8987.00 CAD | -33.66% |
| 2017 Q4 | 1.14 Million CAD | 34.01% |
| 2017 FY | 1.14 Million CAD | 91.02% |
| 2017 Q1 | 13.54 Thousand CAD | 47.11% |
| 2017 Q3 | 854.6 Thousand CAD | 9409.29% |
| 2016 Q4 | 9208.00 CAD | -86.29% |
| 2016 Q3 | 67.17 Thousand CAD | 217.06% |
| 2016 Q2 | 21.18 Thousand CAD | 153.55% |
| 2016 Q1 | 8356.00 CAD | -0.29% |
| 2016 FY | 599.52 Thousand CAD | 0.0% |
| 2015 Q4 | 8380.00 CAD | -93.67% |
| 2015 Q3 | 132.34 Thousand CAD | 53.39% |
| 2015 Q2 | 86.27 Thousand CAD | 43.41% |
| 2015 Q1 | 60.16 Thousand CAD | 0.0% |
| 2014 FY | 60.16 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arch Biopartners Inc. | 6.68 Million CAD | 83.699% |
| Covalon Technologies Ltd. | 6.1 Million CAD | 82.169% |
| Hemostemix Inc. | 7.68 Million CAD | 85.828% |
| Universal Ibogaine Inc. | 2.37 Million CAD | 54.138% |
| Kane Biotech Inc. | 14.09 Million CAD | 92.271% |
| MedMira Inc. | 18.68 Million CAD | 94.171% |
| Marvel Biosciences Corp. | 2.39 Million CAD | 54.479% |
| NervGen Pharma Corp. | 15.24 Million CAD | 92.856% |